GlobeNewswire: Evelo Biosciences, Inc. Contains the last 10 of 133 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:11:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/10/17/2761342/0/en/Evelo-Biosciences-Announces-Top-Line-Results-From-its-Phase-2-Clinical-Study-with-EDP2939-in-Moderate-Psoriasis.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis2023-10-17T11:00:00Z<![CDATA[- Primary endpoint was not achieved –]]>https://www.globenewswire.com/news-release/2023/08/14/2724292/0/en/Evelo-Biosciences-Announces-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights2023-08-14T11:30:00Z<![CDATA[– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation]]>https://www.globenewswire.com/news-release/2023/07/12/2703423/0/en/Evelo-Biosciences-Closes-25-5-Million-Private-Placement.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Closes $25.5 Million Private Placement2023-07-12T11:30:00Z<![CDATA[Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors]]>https://www.globenewswire.com/news-release/2023/07/10/2701677/0/en/Evelo-Biosciences-Announces-25-5-Million-Private-Placement.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Announces $25.5 Million Private Placement2023-07-10T11:30:00Z<![CDATA[CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share, which would result in gross proceeds of approximately $25.5 million. The offering is being led by Evelo’s founder, Flagship Pioneering, with participation from other new and existing investors. Evelo intends to use the net proceeds from the private placement to fund the readout of its Phase 2a trial of EDP2939 in moderate psoriasis, to pay down approximately $5.0 million of its existing debt and for general corporate purposes.]]>https://www.globenewswire.com/news-release/2023/06/29/2697068/0/en/Evelo-Biosciences-Announces-Reverse-Stock-Split-Effective.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Announces Reverse Stock Split Effective2023-06-29T13:00:00Z<![CDATA[– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 –]]>https://www.globenewswire.com/news-release/2023/04/26/2654930/0/en/Evelo-Biosciences-Provides-Clinical-Updates.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Provides Clinical Updates2023-04-26T11:30:00Z<![CDATA[– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV candidate, EDP2939, in Phase 2 moderate psoriasis study fully enrolled; data anticipated in early Q4 2023 –– Management to host conference call today at 8:30 a.m. ET –]]>https://www.globenewswire.com/news-release/2023/03/16/2628499/0/en/Evelo-Biosciences-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights2023-03-16T11:00:00Z<![CDATA[CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022.]]>https://www.globenewswire.com/news-release/2023/03/09/2623776/0/en/Evelo-Biosciences-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-Thursday-March-16-2023.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 20232023-03-09T11:00:00Z<![CDATA[CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights.]]>https://www.globenewswire.com/news-release/2023/03/01/2617946/0/en/Evelo-Biosciences-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference2023-03-01T11:00:00Z<![CDATA[CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.]]>https://www.globenewswire.com/news-release/2023/02/27/2615820/0/en/Evelo-Biosciences-Reports-that-EDP2939-its-First-Oral-Extracellular-Vesicle-Product-Candidate-Commenced-Dosing-in-a-Phase-2-Psoriasis-Trial.html?f=22&fvtc=4&fvtv=47800Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial2023-02-27T11:00:00Z<![CDATA[– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –]]>